Previous Article | Next Article 
Infection and Immunity, April 2001, p. 2277-2285, Vol. 69, No. 4
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.4.2277-2285.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Different Subsets of Enteric Bacteria Induce and
Perpetuate Experimental Colitis in Rats and Mice
Heiko C.
Rath,1,2
Michael
Schultz,1,2
René
Freitag,2
Levinus A.
Dieleman,1
Fengling
Li,1
Hans-Jörg
Linde,3
Jürgen
Schölmerich,2 and
R. Balfour
Sartor1,*
Center for GI Biology and Disease, University
of North Carolina, Chapel Hill, North Carolina,1
and Department of Internal Medicine
I2 and Institute of Medical
Microbiology and Hygiene,3 University of
Regensburg, Regensburg, Germany
Received 18 September 2000/Returned for modification 2 November
2000/Accepted 28 December 2000
 |
ABSTRACT |
Resident bacteria are incriminated in the pathogenesis of
experimental colitis and inflammatory bowel diseases. We investigated the relative roles of various enteric bacteria populations in the
induction and perpetuation of experimental colitis. HLA-B27 transgenic
rats received antibiotics (ciprofloxacin, metronidazole, or
vancomycin-imipenem) in drinking water or water alone in either prevention or treatment protocols. Mice were treated similarly with
metronidazole or vancomycin-imipenem before or after receiving 5%
dextran sodium sulfate (DSS). Germfree transgenic rats were colonized
with specific-pathogen-free enteric bacteria grown overnight either in
anaerobic or aerobic atmospheres. Nontransgenic rats colonized with
anaerobic bacteria served as negative controls. Although preventive
metronidazole significantly attenuated colitis in transgenic rats and
DSS-treated mice, it had no therapeutic benefit once colitis was
established. Ciprofloxacin also partially prevented but did not treat
colitis in B27 transgenic rats. In both animal models
vancomycin-imipenem most effectively prevented and treated colitis.
Germfree transgenic rats reconstituted with enteric bacteria grown
under anaerobic conditions had more aggressive colitis than those
associated with aerobic bacteria. These results suggest that a subset
of resident luminal bacteria induces colitis, but that a complex
interaction of commensal aerobic and anaerobic bacteria provides the
constant antigenic drive for chronic immune-mediated colonic inflammation.
 |
INTRODUCTION |
Rapidly growing evidence supports the influence of normal enteric
bacteria on the pathogenic process of intestinal inflammation and
extraintestinal manifestations in experimental colitis and human
inflammatory bowel diseases (IBD) (40-43). Both
spontaneous and induced inflammation in multiple widely diverse rodent
models have been associated with commensal luminal bacteria (1,
11-13, 16, 22, 31, 44, 45, 52, 54). The influence of resident bacteria on the induction and perpetuation of spontaneous colitis and
gastritis has been thoroughly studied in
HLA-B27/
2-microglobulin transgenic (B27 TG) rats.
Colitis, gastritis, and joint inflammation fail to develop in B27 TG
rats raised under germfree (sterile) conditions (36, 49).
Moreover, when transferred into a specific-pathogen-free (SPF)
environment, B27 TG rats universally develop immune-mediated colitis
and gastritis within 1 month of bacterial colonization (36).
However, not all luminal bacteria have equal abilities to cause
inflammation. Antibiotics with narrow specificities, such as
metronidazole, which is selectively active against anaerobic bacteria,
are effective in Crohn's colitis and ileocolitis (47) and
also attenuate chronic experimental intestinal inflammation induced by
indomethacin or carageenan in rats and guinea pigs, respectively
(32, 54). In addition, overgrowth of predominantly anaerobic bacteria in bypassed small intestinal segments can lead to
systemic inflammation. A jejunal self-filling blind loop induces hepatobiliary inflammation resembling sclerosing cholangitis and reactivates quiescent arthritis in genetically susceptible Lewis or
Wistar rats (24, 25), and some patients undergoing
surgical treatment for morbid obesity with creation of bypassed
jejunoileal segments develop arthritis and hepatic and skin
inflammation (8). In both examples, metronidazole or
broad-spectrum antibiotics with anaerobic specificities can reverse
these systemic manifestations (15, 23, 25). Creating a
cecal self-filling blind loop in B27 TG rats alters the cecal bacterial
composition by significantly increasing luminal concentrations of
Bacteroides spp. and anaerobic bacteria relative to aerobic
flora (37). This manipulation of cecal bacterial
composition markedly enhances cecal inflammation in these rats, with
submucosal inflammation and mucosal ulcers extending to the muscle
layer (37). Furthermore, exclusion of the cecum from the
fecal stream decreases the total bacterial load in the cecum and
results in almost complete healing of cecal inflammation and gastritis,
although the concentration of gastric bacteria does not change
(37). The most convincing evidence for selective induction
of experimental gastrointestinal inflammation with subsets of resident
bacteria is provided by reconstitution studies in gnotobiotic B27 TG
rats. Previously germfree B27 TG rats colonized with six different
obligate and facultative intestinal anaerobic bacteria including
Bacteroides vulgatus develop much more active colitis and
gastritis than littermates colonized with the same selected bacteria
without B. vulgatus (36). Of note, B27 TG rats
colonized with a full complement of SPF bacteria had more inflammation
than the B27 TG gnotobiotic rats colonized with the six bacterial
species including B. vulgatus. The importance of B. vulgatus in induction of colitis in this model was confirmed by
monoassociation studies, in which B. vulgatus but not
Escherichia coli induced colitis equal to that induced by
the group of six investigated bacterial species (38).
Interestingly, TG rats monoassociated with B. vulgatus
failed to develop gastritis, which was routinely present in gnotobiotic
rats colonized with the six different bacterial strains
(38) and in SPF B27 TG rats (36). However,
Onderdonk et al. (33) reported that high concentrations of
E. coli and Enterococcus species were associated
with severe colitis in B27 TG rats. These results suggest that
anaerobic bacteria, especially B. vulgatus, have a key role
in initiating colitis in B27 TG rats and that other bacterial species,
although unable to initiate colitis independently, have an important
role in mediating inflammation in remote organs such as the stomach and
modulating the intensity of colitis.
Colitis induced by dextran sodium sulfate (DSS) in BALB/c mice was
first described in 1990 by Okayasu et al. (30) and is now
an established induced model of acute and chronic colitis. Its
association with enteric bacteria is well described (28, 30). Okayasu et al. reported significant increases in the
population of members of the bacterial species Bacteroides,
Enterobacter, and Clostridium but decreases in
Eubacterium spp. and Enterococcus spp. after
acute DSS colitis (30). Bacteroides spp. were
identified as predominantly Bacteroides distasonis.
Protective effects of metronidazole and the combination of
metronidazole and ciprofloxacin in acute DSS colitis were demonstrated
by Ohkusa et al. (29) and Hans et al (19).
However, Axelsson et al. (6) have reported that acute DSS
colitis can be induced even in a germfree environment and is not
significantly different than intestinal inflammation in rodents
maintained in a conventional environment, suggesting a direct toxic
effect of DSS. In contrast, other investigators found significantly
attenuated colitis in germfree mice treated with DSS (50).
Several groups have demonstrated that colitis occurs in SCID mice
treated for short periods with DSS (5, 14), suggesting
that T lymphocytes, B cells, and NK cells are not essential in the
acute phase of DSS colitis. Of interest, sulfasalazine treated colitis
in germfree DSS mice, even in the absence of bacteria, which are
essential to split sulfasalazine into active 5 amino salicylic acid
(5-ASA) (4).
To help determine which broad subsets of the complex resident luminal
bacterial population preferentially initiate and perpetuate colitis in
two distinctly different rodent models, we administered several
antibiotics with selective antimicrobial activities to B27 TG rats and
BALB/c mice with DSS-induced colitis before and after the onset of
intestinal inflammation. In addition, we colonized germfree B27 TG rats
with commensal cecal bacteria grown under aerobic or anaerobic
conditions. B27 TG rats were selected because these rats develop
well-characterized chronic T-lymphocyte-mediated inflammation when
exposed to resident nonpathogenic enteric bacteria. The DSS model was
chosen to determine which commensal bacteria mediate acute induced
intestinal inflammation.
 |
MATERIALS AND METHODS |
Animals.
Colonies of B27 TG rats and nontransgenic (NT)
littermates on a Fischer F344 background (18), originally
obtained from Joel D. Taurog (Southwestern Medical School, Dallas,
Tex.), were housed and maintained in an SPF environment and under
germfree conditions (36). SPF female BALB/c mice were
obtained from Charles River, Sulzfeld, Germany, and housed under
standard conditions.
Experimental design.
B27 TG rats raised in an SPF
environment were treated with either antibiotics in drinking water or
water alone (as controls) in prevention and treatment protocols. NT
rats housed under identical conditions served as negative controls.
Prevention (TG rats given water, n = 8; TG rats given
ciprofloxacin, n = 8; TG rats given metronidazole,
n = 9; TG rats given vancomycin-imipenem, n = 9; NT rats given water, n = 9) started at 4 weeks of age, soon after weaning and prior to the onset of colitis,
which develops between 2 and 3 months of age in SPF conditions at our
institution (36). Treatment (TG rats given water,
n = 5; TG rats given ciprofloxacin, n = 8; TG rats given metronidazole, n = 8; TG rats
given vancomycin-imipenem, n = 8; NT rats given water,
n = 9) was begun at 3 months of age, when SPF B27 TG
rats have developed colitis by gross, histologic, and immunologic
parameters (36). All rats were killed at 4 months of age,
after 1 month of antibiotic treatment and 3 months of prevention. At
necropsy cecal tissues were taken for histology and determination of
interleukin-1
(IL-1
) protein, which has been validated as an
indicator of tissue inflammation (36-38). The antibiotics
used in this experiment were selected for their activities against
various enteric bacterial populations. Metronidazole (40 mg/kg of body
weight/day) is selectively active against anaerobic bacteria, including
gram-negative bacteria such as Bacteroides spp., whereas
ciprofloxacin (50 mg/kg/day) is most effective against enteric aerobic
gram-negative organisms, with an extended spectrum to anaerobic
gram-positive bacteria. Imipenem (50 mg/kg/day), is a
very-broad-spectrum antimicrobial drug with efficacy against almost all
gram-positive and gram-negative bacteria, including anaerobes, except
methicillin-resistant staphylococci, enterococci, and some
Pseudomonas spp. Vancomycin (50 mg/kg/day) was added to
imipenem to cover staphylococci and enterococci.
Acute colitis in BALB/c mice was established by adding 5% DSS (ICN
Biomedicals Inc., Aurora, Ohio) to drinking water for 7 days (20,
30). DSS-treated mice were also treated with either metronidazole (40 mg/kg/day) or vancomycin-imipenem (50 mg/kg/day) in
drinking water or with water alone as a positive control. Water consumption was monitored on a daily basis. We were unable to administer ciprofloxacin, since mice refused to drink water containing this agent. Prevention started 3 days before DSS administration, and
treatment began 2 days after the onset of DSS feeding. All mice
(n = 5 for each group) were killed on day 7. At
necropsy cecal tissues were taken for histology.
B27 TG rats and NT littermates raised under germfree conditions
(36) were divided in two groups at the age of 2 months. Both groups were transferred into separate isolators and colonized with
different bacterial populations by oral and anal gavage of 1 ml of
culture medium containing the bacteria and placing 0.5 ml on food
pellets as previously described (36). One group of B27 TG
rats (n = 6) received fecal bacteria from SPF TG rats; the bacteria were incubated overnight in a thioglycolate broth in an
anaerobic 5% CO2-10% H2-85% N2
atmosphere. The second group of B27 TG rats (n = 9)
received fecal bacteria from the same rat which were grown overnight in
brain heart infusion broth under aerobic conditions. NT rats
(n = 9) with fecal bacteria grown under anaerobic
conditions served as negative controls. Rats were killed 1 month after
bacterial colonization.
Gross inflammatory scores.
At necropsy the degree of
thickening of the mid-cecum of rats was blindly scored using a
previously validated scale from 0 to 4+ scale (36).
Histology.
Tissues were prepared as previously described
(36). A validated histologic inflammatory score ranging
from 0 to 4+ was used for blinded evaluation of cecal inflammation in
the B27 TG rats (36). This score was adapted to mice with
DSS-induced colitis.
Rat IL-1
enzyme-linked immunosorbent assay.
We measured
IL-1
protein concentrations in homogenized cecal tissues by
enzyme-linked immunosorbent assay as previously described (37), using antibodies that were provided by S. Poole,
National Institute of Biological Standards and Controls, Hertfordshire, United Kingdom. We previously have documented upregulation of IL-1 and
other proinflammatory cytokines produced by activated macrophages in
SPF B27 TG rats (36) and correlated tissue IL-1
with
histology scores and tissue myeloperoxidase (36-38).
Determination of luminal bacterial concentrations.
The ceca
of euthanized non-B27 TG rats were removed, and 1 ml of cecal contents
was taken immediately, weighed, and serially diluted in prereduced
thioglycolate broth. From every dilution 100 µl was plated on
prereduced anaerobically sterilized agar plates in an anaerobic 5%
CO2-10% H2-85% N2 atmosphere.
Aerobic culture was performed using blood agar plates. Colonies were
counted after 2 (aerobic culture) and 6 (anaerobic culture) days of
incubation at 37°C. Bacteroides spp. were selectively
grown on Bacteroides Bile Esculin agar under anaerobic
conditions. Morphology was checked by Gram staining. Total bacterial
concentrations were determined on serial dilutions with phase-contrast
microscopy using a Neubauer counting chamber. Identification of
presumed Bacteroides spp. was performed by standard
procedures (46). Results were normalized for stool dry weights.
Statistical analysis.
All data are expressed as the
mean ± standard error of the mean (SEM). After testing for equal
distribution, analysis of variance was used to test for differences
between the groups. Gross and histologic inflammatory scores, tissue
IL-1
levels, and fecal bacterial concentrations with equal
distribution were compared to the control group (TG rats given water)
using multiple-comparison procedures (Bonferroni t test).
Gross and histologic inflammatory scores which did not pass the equal
distribution test were analyzed using the nonparametric Kruskal-Wallis
one-way analysis of variance on ranks and Dunn's method for the
multiple-comparison procedures. All tests were performed using
SigmaStat software from SSPS Inc. A P value of <0.05 was
considered statistically significant.
 |
RESULTS |
Antibiotics.
To determine which broad classes of
luminal bacteria are responsible for initiation of colitis, 4-week-old
SPF B27 TG rats were given antibiotics with selective activities prior
to onset of colitis (preventive protocol). The same antibiotics were
administered to 3-month-old B27 TG rats after onset of colitis in a
therapeutic protocol. The degree of colitis was measured by blinded
gross and histologic scores as well as tissue IL-1
concentration,
which is a validated marker of macrophage activation and inflammation in this model (36-38). Although preventive metronidazole
significantly attenuated colitis in B27 TG rats grossly (0.5 ± 0.2, versus 1.6 ± 0.3 for B27 TG rats given water; P < 0.05) and histologically (P < 0.001) (Fig.
1), there was no benefit in treating with
metronidazole once colitis was established (gross gut score, 1.6 ± 0.3 for metronidazole versus 1.9 ± 0.6 water [not significant
{NS}]) (Fig. 1 and 2A and B). These
results were confirmed by cecal IL-1
(Fig.
3). Similarly, mice were treated with
antibiotics 3 days before (prevention) or 2 days after (treatment)
onset of DSS administration. Metronidazole reduced the severity of
DSS-induced colitis when given prophylactically to mice (P = 0.01) (Fig. 4), but there was no
statistically significant therapeutic effect. The effect of
ciprofloxacin on histologic scores was similar to that of metronidazole
(P < 0.05 in prevention, NS in treatment) (Fig. 1),
but it did not significantly reduce the gross scores (prevention,
0.4 ± 0.1 [NS]; treatment, 1.2 ± 0.3 [NS]) or tissue
IL-1
concentrations (Fig. 3) with either protocol.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 1.
Blinded histologic scores of the ceca from B27 TG
treated with different antibiotics starting before (4 weeks of age,
prevention protocol) ( ) and after (3 months of
age, treatment protocol) ( ) the onset of colitis. All rats
were killed at 4 months of age. n = 8 or 9 rats in each
group. *, P < 0.05 versus TG water controls. Cipro,
ciprofloxacin; Metro, metronidazole; Vanco, vancomycin. Error bars
indicate SEMs.
|
|

View larger version (104K):
[in this window]
[in a new window]
|
FIG. 2.
(A) Photomicrograph of cecal inflammation in a
4-month-old SPF B27/ 2-microglobulin TG rat treated with
water alone. (B) A TG rat treated with metronidazole after the onset of
colitis (3 months of age) showed only slight reduction of cecal
inflammation. (C) The cecum of a TG rat treated with
vancomycin-imipenem after the onset of colitis (3 months of age)
revealed substantially less cecal inflammation. (D) Normal cecum of a
4-month-old NT control rat treated with water alone.
|
|

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 3.
Tissue IL-1 protein concentrations of the ceca from
B27 TG rats treated with different antibiotics starting before (4 weeks
of age) ( ) and after (3 months of age) ( )
the onset of colitis. *, P < 0.05 versus TG water.
Cipro, ciprofloxacin; Metro, metronidazole; Vanco, vancomycin. Error
bars indicate SEMs.
|
|

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 4.
Blinded histologic scores of the ceca from BALB/c mice
with DSS-induced colitis treated with different antibiotics starting 3 days before or 2 days after the onset of DSS administration. The 5%
DSS was continued for a total of 7 days. *, P < 0.05
versus water. , Prevention; , treatment;
, water control. Error bars indicate SEMs.
|
|
In both animal models broad-spectrum antibiotic therapy with combined
vancomycin-imipenem was effective in both prevention (gross score,
0.2 ± 0.1 [P < 0.05]; histologic scores,
P < 0.0001 [Fig. 1 and 4]; IL-1
, P < 0.01 [Fig. 3]) and treatment of established colitis (gross
score, 0.3 ± 0.1 [P < 0.01]; histologic
scores, P < 0.0001 [Fig. 1, 2A and C, and 4];
IL-1
, P < 0.05 [Fig. 3]). However, even
vancomycin-imipenem did not completely abrogate histologic inflammation
in the B27 TG rats (histologic score, P < 0.005 versus
NT control rats given water [Fig. 1]), although there was no
difference in IL-1
concentrations relative to NT control rats given
water (Fig. 3). In contrast, this broad-spectrum antibiotic combination
almost completely blocked DSS-induced colitis (Fig. 4).
These results indicate that selective antibiotics can attenuate the
onset of colitis in two disparate models, but only broad-spectrum treatment can reverse established disease. These data suggest that both
aerobic and anaerobic bacteria can initiate inflammation but that a
more complex group of bacteria is required to perpetuate disease.
Microbial assessments.
We then measured total cecal
concentrations of bacteria in antibiotic-treated versus water-treated
control rats as well as the relative concentrations of anaerobic and
aerobic subsets and Bacteroides species, which have been
implicated in the pathogenesis of colitis in B27 TG rats (36,
38). Total cecal bacterial concentrations in the rats were
significantly reduced after 4 weeks of antibiotic treatment in all
therapeutic groups relative to the water-treated controls (control,
2.7 × 1010 ± 1.0 × 1010 CFU/g of
stool; vancomycin-imipenem, 2.0 × 108 ± 0.8 × 108 CFU/g of stool [P < 0.025 versus control]; metronidazole, 1.9 × 109 ± 0.6 × 109 CFU/g of stool
[P < 0.035 versus control]; ciprofloxacin, 3.9 × 109 ± 0.5 × 109 CFU/g of stool
[P < 0.045 versus control]) (Fig.
5) but were lowest in the
vancomycin-imipenem-treated animals (P < 0.02 versus metronidazole and P < 0.0002 versus ciprofloxacin)
(Fig. 5), which had at least 1-log-unit-fewer organisms than all other
groups. Sequential evaluation of cecal bacterial concentrations
revealed an initial 1,000-fold decrease of intestinal flora after 3 weeks of therapy with vancomycin-imipenem (5.4 × 107
CFU/g) with a subsequent increase in cecal concentrations to 1.3 × 109 CFU/g after 6 weeks, which was still 50-fold less
than those in water-treated controls. The interval increase in
bacterial concentration between 3 and 6 weeks of antibiotic
administration was minimal in the metronidazole-treated group and no
increase was seen in the ciprofloxacin-treated group, although the
initial decrease was not nearly as marked as with combination therapy (data not shown). At the end of 8 weeks of antibiotic treatment cecal
Bacteroides spp. were absent in the metronidazole-and
vancomycin-imipenem-treated groups (with one exception in the
vancomycin-imipenem-treated group) but were detected in all animals of
the ciprofloxacin-treated and control groups. The ratio of
anaerobically to aerobically grown bacteria (reflecting the
concentration of obligate anaerobic bacteria) compared with that in the
control group after three weeks of antibiotic therapy was 0.5 in the
vancomycin-imipenem-treated group, 0.1 in the metronidazole-treated
group, and 1.5 in the ciprofloxacin-treated group and did not change
over the treatment period (Fig. 6),
suggesting a strong decrease of obligate anaerobic bacteria in the
metronidazole-treated group, a decrease of both aerobic and anaerobic
bacteria in the vancomycin-imipenem-treated group (with slightly more
effect on anaerobes than aerobes), and a selective decrease of aerobic
bacteria in the ciprofloxacin-treated group. These results suggest that
the decrease in luminal bacterial concentrations correlates with the
therapeutic efficacy of antibiotics, that both aerobic and anaerobic
bacterial populations are implicated in disease, and that while
Bacteroides spp. may be important in the pathogenesis of
disease, clearly other bacterial strains have contributory roles.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 5.
Total bacterial concentrations in the cecal contents of
NT rats treated with different antibiotics for 4 weeks, measured in a
counting chamber. *, P < 0.05 versus control; §,
P < 0.05 versus ciprofloxacin (Cipro) and
metronidazole (Metro). Vanco, vancomycin. Error bars indicate SEMs.
|
|

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 6.
Alteration of the ratio of anaerobic bacteria to aerobic
bacteria by antibiotics compared to the ratio of anaerobic bacteria to
aerobic bacteria in the water control group ([anaerobes/aerobes with
antibiotics]/[anaerobes/aerobes for water control]). Antibiotic
treatment resulted in an altered bacterial composition after 6 weeks.
Compared with the water controls, vancomycin-imipenem reduced more
anaerobes than aerobes as demonstrated by the decreased ratio of
anaerobes to aerobes to 0.5 of that of the water control group. This
alteration of bacterial composition was even exceeded by metronidazole,
where the ratio of anaerobes to aerobes dropped to 1/10 of that of the
water control group. In contrast ciprofloxacin reduced predominantly
aerobes as shown by the increase of the anaerobic/aerobic ratio to
1.5-fold that of the water control group.
|
|
Reconstitution with enteric bacteria cultured under aerobic versus
anaerobic conditions.
We then populated germfree B27 TG rats with
aerobically and anaerobically cultivated enteric bacteria to determine
the relative abilities of these subsets to induce experimental colitis.
Rats were maintained in Trexler isolators with sterile food and water for 1 month to prevent colonization with other organisms. Both groups
of rats had similar concentrations of fecal bacteria (1012
CFU/g of stool), which were comparable to levels in SPF rats. B27 TG
germfree rats colonized with a culture of SPF fecal flora incubated for
24 h in an anaerobic atmosphere developed more aggressive cecal
inflammation than littermates associated with aerobically cultivated
bacteria from the same source (histology scores, 2.3 ± 0.2 for
anaerobic atmosphere versus 1.4 ± 0.1 for aerobic atmosphere [P < 0.01]) (Fig. 7).
However, B27 TG rats colonized with the aerobic flora had significantly
more inflammation than NT littermates colonized with anaerobes, which
had no evidence of colitis (0.3 ± 0.1 [P < 0.0001]). These experiments indicate that both aerobic and
anaerobic nonpathogenic commensal bacteria can induce colitis in
genetically susceptible rats, but the anaerobic population is more
aggressive in this model, despite equal fecal concentrations of the two
bacterial subsets.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 7.
Blinded histologic scores of the ceca from germfree B27
TG rats colonized for 1 month with cultures of SPF cecal bacteria
incubated overnight under anaerobic or aerobic conditions. n = 6 to 9 rats/group. *, P < 0.05 versus
anaerobic; §, P < 0.05 versus aerobic. Error bars
indicate SEMs.
|
|
 |
DISCUSSION |
Growing evidence in the past five years has supported the crucial
role of enteric bacteria in the pathogenesis of chronic intestinal
inflammation (41, 42). However, rodent models indicate that not all bacteria have equal capabilities of inducing
gastrointestinal inflammation. Our present data further illustrate the
complexities of bacterial composition in the pathogenesis of
experimental colitis in two different rodent models. In the present
study we used the DSS model as a prototype of an acute inducible
colitis and the B27 TG rat model as an example of spontaneous,
TH1 chronic immune-mediated gastrointestinal inflammation
in a genetically engineered host (36, 48).
One major finding of the present study is the lack of therapeutic
effects for antibiotics with narrow specificities. Metronidazole was
unable to treat inflammation once colitis was established, although it
was effective in both animal models in a prevention protocol. On the
other hand, the broad-spectrum combination of vancomycin-imipenem was
able to more effectively prevent colitis as well as treat established
disease. These results are consistent with our previous observation
that monoassociation of gnotobiotic B27 TG rats with B. vulgatus induced colitis which was less aggressive than that
present in SPF B27 TG rats (36, 38). Together these antibiotic and gnotobiotic studies suggest a predominant role for
Bacteroides spp. in initiating colitis in this model, with a
synergistic effect of an unknown number of other enteric bacteria in
perpetuating and mediating disease (37, 38). However, the observation that the broad-spectrum combination of vancomycin-imipenem was also significantly more effective than metronidazole in preventing colitis suggests initial proinflammatory capabilities from bacterial species other than Bacteroides, since Bacteroides
spp. were undetectable in both metronidazole and vancomycin-imipenem
treatment groups. The ability of certain aerobic bacteria to initiate
inflammation is further supported by the induction of mild colitis by
colonization of germfree B27 TG rats with aerobic bacteria and a modest
protective effect of ciprofloxacin in the present study. Videla et al.
and Mourelle et al. also showed that the vancomycin-imipenem
combination was superior to single antibiotics, including
metronidazole, in experimental colitis induced by trinitrobenzene
sulfonic acid (53) and could prevent fibrosis in these
rats with induced colonic ulcers (27). Likewise, Madsen et
al. (26) reported that the combination of metronidazole
and neomycin prevented and treated colitis in IL-10-deficient mice and
was superior to ciprofloxacin, which prevented the onset of colonic
inflammation but only partially reversed established colitis, while
Hans et al. (19) demonstrated that intraperitoneal
metronidazole plus ciprofloxacin could improve acute but not chronic
DSS-induced colitis. Clinical trials further support the ability of
metronidazole to prevent Crohn's disease with modest therapeutic
effects as a single agent but improved efficacy in combination with
other antibiotics. Rutgeerts et al. (39) demonstrated that
metronidazole given after curative ileal resection for 3 months
significantly decreased postoperative recurrence of Crohn's disease
for up to 1 year. In a therapeutic protocol monotherapy with
metronidazole significantly decreased the Crohn's disease activity
index in patients with colitis and ileocolitis but had no effect on
patients with isolated ileal disease and did not lead to a significant
induction of remission (Crohn's disease activity index, <150)
(47). More recently, Prantera et al. (35)
reported that metronidazole in combination with ciprofloxacin was
effective in the treatment of moderately active Crohn's disease.
The preventive effect of ciprofloxacin in B27 TG rats, although
supported only by blinded histologic score and not by IL-1
tissue
concentration, was somewhat surprising in light of our previous
observations that B. vulgatus has a preferential ability to
induce colitis in this model (36, 38). Although others report some effect of ciprofloxacin on Bacteroides spp.
(34), in our hands ciprofloxacin given in drinking water
reduced total intestinal bacterial concentrations less than 1 log unit
and had no effect on Bacteroides spp. Unfortunately we were
unable to test these findings in DSS-treated mice, since these mice
refused to drink water containing ciprofloxacin. Similarly, Madsen et al. (26) showed only a modest decrease (1 log unit) in
mucosally adherent-invasive Bacteroides spp. following 8 weeks of oral ciprofloxacin treatment in IL-10
/
mice,
in contrast to clearance of all detectable Bacteroides with
neomycin-metronidazole administration. The lack of any effect of
preventive ciprofloxacin on the gross gut score and tissue IL-1
level in our study and the preliminary results of Braat et al.
(7), where IL-10
/
mice treated either
preventively or therapeutically with the same dose of ciprofloxacin
received no benefit, and of Madsen et al. (26), where
ciprofloxacin had only a modest therapeutic benefit in established
colitis in IL-10
/
mice, are in contrast to our observed
histologic findings. Similarly, reports of the clinical effect of
ciprofloxacin in IBD are somewhat inconsistent. Turunen et al.
described a concomitant role of this antibiotic in preventing relapse
of ulcerative colitis (51) but no effect on Crohn's
disease using a similar protocol. However, recent reports by Colombel
et al. (9) and preliminary data by Arnold et al.
(3) demonstrated beneficial therapeutic effects of
ciprofloxacin in mild to moderate active Crohn's disease. Gionchetti et al. have demonstrated efficacy of ciprofloxacin in combination with
a broad-spectrum nonabsorbable antibiotic, rifaximin, in refractory
pouchitis (17). These results suggest that aerobic gram-negative bacteria contribute to intestinal inflammation, which is
supported by our observations of modest induction of experimental
colitis in B27 TG rats obtained by aerobic cultures of cecal contents
and by data from Onderdonk and colleagues, who revealed a dramatic
increase of E. coli and Enterococcus spp. in
cecal contents of HLA-B27 transgenic rats with severe chronic colitis
(33).
The mechanism of action of metronidazole has been questioned in light
of the possible direct immunomodulating capabilities of this antibiotic
in indomethacin-induced small bowel inflammation (2, 10).
In support of an antimicrobial role of metronidazole in our
experiments, we demonstrated a prolonged suppression of Bacteroides spp. with chronic administration of
metronidazole and with imipenem-vancomycin, which were the agents which
most effectively prevented colitis in the B27 TG rats. Germfree B27 TG
rats colonized with SPF fecal bacterial flora grown overnight under
anaerobic conditions developed active colitis, whereas population with
aerobic bacterial cultures devoid of all obligate anaerobic species,
including Bacteroides, produced only mild inflammation. While these experiments do not exclude a possible synergistic immunomodulatory effect of metronidazole, they indicate the importance of obligate anaerobic bacteria in the pathogenesis of colitis in this model.
Microbial assessment following antibiotic therapy revealed interesting
findings. Although vancomycin-imipenem predictably suppressed bacterial
counts after 3 weeks of administration, this was a transient effect
with a 2-log-unit rebound in total bacterial counts between 3 and 6 weeks, consistent with the proliferation of resistant bacteria which
partially repopulated the colon despite continued antibiotic
administration. However, after 6 weeks of vancomycin-imipenem
administration, total luminal bacterial counts remained 1 log unit less
than control levels. This delayed increase in bacterial concentrations
was less evident with metronidazole treatment and was absent with
ciprofloxacin therapy. The discrepancy between the prolonged
therapeutic effect of vancomycin-imipenem administration and increasing
bacterial concentrations suggests that this combination of antibiotics
may have a lasting effect on colitis by altering some components of the
bacterial milieu in a sustained fashion. This concept is supported by
lack of detection of Bacteroides spp. even after 8 weeks of
therapy with vancomycin-imipenem despite a rebound in total bacterial
counts. Therapeutic effects of protracted administration of
vancomycin-imipenem may be prolonged because of the long-term
elimination of Bacteroides spp. and possibly other resident
bacterial species, which may be sufficient to prevent recurrence after
induction of remission. Metronidazole, which also permanently
suppressed Bacteroides spp., was able to prevent onset of
colitis in B27 TG rats and to prevent relapse of Crohn's disease after
a surgically induced remission (39). Clinical studies have
shown that chronic metronidazole therapy can eliminate fecal
Bacteroides for at least 6 months (21).
The present study convincingly reveals an important but complex effect
of luminal bacteria in the acute phase as well as the chronic phase of
experimental colitis. The present results in conjunction with our
previous observations strongly support the following hypotheses (i)
Normal luminal bacteria are required for development of chronic
immune-mediated intestinal inflammation. (ii) Commensal enteric
bacterial species have unequal proinflammatory capabilities, with some
being more aggressive than others. (iii) Various endogenous bacteria
have different roles in the inflammatory process. Some, including
Bacteroides spp. and other, yet-to-be identified species
partially suppressed by ciprofloxacin and more completely
eliminated by vancomycin-imipenem, preferentially initiate inflammation, while another, perhaps larger spectrum of intestinal bacteria perpetuate disease. (iv) An initial reduction of the total
bacterial load with a broad-spectrum antibiotic combination alters the
bacterial composition with a lasting effect on intestinal inflammation,
although the total luminal concentration recovers rapidly.
These findings have important clinical therapeutic implications and lay
the foundation for clinical trials of broad-spectrum antibiotics or
antibiotic combinations in human IBD. It may be possible to treat
active Crohn's disease with a broad-spectrum antibiotic combination
until remission is achieved and then switch to prophylactic therapy
with metronidazole.
 |
ACKNOWLEDGMENTS |
We gratefully acknowledge the expert technical support of lnes
Melchner, Julie Vorobiov, and Wethonia B. Grenther; the secretarial expertise of Susie May; and the assistance of the Histology and Immunoassay Cores in the Center for Gastrointestinal Biology and Disease at the University of North Carolina, Chapel Hill.
These studies were supported by U.S. Public Health Service grants DK
34987, DK 40249, and DK 53347; the Crohn's and Colitis Foundation of
America (CCFA); the Deutsche Morbus Crohn und Colitis Ulcerosa
Vereinigung (DCCV); and Deutsche Forschungsgemeinschaft (DFG) grants Ra
671/1-1 and Sch 1131/1-2.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Division of
Digestive Diseases, CB#7038, Room 032A Glaxo Bldg., University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7038. Phone: (919) 966-0149. Fax: (919) 966-7468. E-mail: rbs{at}med.unc.edu.
Editor:
J. D. Clements
 |
REFERENCES |
| 1.
|
Aranda, R.,
B. C. Sydora,
P. L. McAllister,
S. W. Binder,
H. Y. Yang,
S. R. Targan, and M. Kronenberg.
1997.
Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RBhigh T cells to SCID recipients.
J. Immunol.
158:3464-3473[Abstract].
|
| 2.
|
Arndt, H.,
K. D. Palitzsch,
M. B. Grisham, and D. N. Granger.
1994.
Metronidazole inhibits leukocyte-endothelial cell adhesion in rat mesenteric venules.
Gastroenterology
106:1271-1276[Medline].
|
| 3.
|
Arnold, G. L.,
H. Patel,
M. Beaves, and H. Boyd.
1999.
Ciprofloxacin in active Crohn's disease: preliminary report of a six month randomized placebo controlled study.
Gastroenterology
116:A664.
|
| 4.
|
Axelsson, L. G.,
E. Landstrom, and A. C. Bylund-Fellenius.
1998.
Experimental colitis induced by dextran sulphate sodium in mice: beneficial effects of sulphasalazine and olsalazine.
Aliment. Pharmacol. Ther.
12:925-934[CrossRef][Medline].
|
| 5.
|
Axelsson, L. G.,
E. Landstrom,
T. J. Goldschmidt,
A. Gronberg, and A. C. Bylund-Fellenius.
1996.
Dextran sulfate sodium (DSS) induced experimental colitis in immunodeficient mice: effects in CD4(+) -cell depleted, athymic and NK- cell depleted SCID mice.
Inflamm. Res.
45:181-191[CrossRef][Medline].
|
| 6.
|
Axelsson, L. G.,
T. Midtvedt, and A. C. Bylund-Fellenius.
1996.
The role of intestinal bacteria, bacterial translocation and endotoxin in dextran sodium sulphate-induced colitis in the mouse.
Microb. Ecol. Health Dis.
9:223-225.
|
| 7.
|
Braat, H.,
L. A. Dieleman,
R. K. Sellon,
M. Schultz, and R. B. Sartor.
1998.
Effects of antibiotics on the initiation and perpetuation of colitis in the IL-10 KO mice.
Gastroenterology
114:G3853.
|
| 8.
|
Brown, R. G.,
J. P. O'Leary, and E. R. Woodward.
1974.
Hepatic effects of jejunoileal bypass for morbid obesity.
Am. J. Surg.
127:53-58[CrossRef][Medline].
|
| 9.
|
Colombel, J. F.,
M. Lemann,
M. Cassagnou,
Y. Bouhnik,
B. Duclos,
J. L. Dupas,
B. Notteghem, and J. Y. Mary.
1999.
A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease.
Am. J. Gastroenterol.
94:674-678[CrossRef][Medline].
|
| 10.
|
Colpaert, S. A.,
Z. Liu,
J. L. Ceuppens,
K. Geboes, and P. Rutgeerts.
2000.
Comparative study on the in vivo efficacy of metronidazole, aztreonam and amoxycillin/clavulanic acid in the indomethacin model: evidence for immuno-modulatory properties of metronidazole.
Gastroenterology
118:A2986.
|
| 11.
|
Cong, Y.,
S. L. Brandwein,
R. P. McCabe,
A. Lazenby,
E. H. Birkenmeier,
J. P. Sundberg, and C. O. Elson.
1998.
CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease.
J. Exp. Med.
187:855-864[Abstract/Free Full Text].
|
| 12.
|
Contractor, N. V.,
H. Bassiri,
T. Reya,
A. Y. Park,
D. C. Baumgart,
M. A. Wasik,
S. G. Emerson, and S. R. Carding.
1998.
Lymphoid hyperplasia, autoimmunity, and compromised intestinal intraepithelial lymphocyte development in colitis-free gnotobiotic IL-2-deficient mice.
J. Immunol.
160:385-394[Abstract/Free Full Text].
|
| 13.
|
Dianda, L.,
A. M. Hanby,
N. A. Wright,
A. Sebesteny,
A. C. Hayday, and M. J. Owen.
1997.
T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment.
Am. J. Pathol.
150:91-97[Abstract].
|
| 14.
|
Dieleman, L. A.,
B. U. Ridwan,
G. S. Tennyson,
K. W. Beagley,
R. P. Bucy, and C. O. Elson.
1994.
Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice.
Gastroenterology
107:1643-1652[Medline].
|
| 15.
|
Drenick, E. J.,
J. Fisler, and D. Johnson.
1982.
Hepatic steatosis after intestinal bypass prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition.
Gastroenterology
82:535-548[Medline].
|
| 16.
|
Garcia-Lafuente, A.,
M. Antolin,
F. Guarner,
E. Crespo,
A. Salas,
P. Forcada,
M. Laguarda,
J. Gavalda,
J. A. Baena,
J. Vilaseca, and J. R. Malagelada.
1997.
Incrimination of anaerobic bacteria in the induction of experimental colitis.
Am. J. Physiol.
272:G10-G15[Abstract/Free Full Text].
|
| 17.
|
Gionchetti, P.,
F. Rizzello,
A. Venturi,
F. Ugolini,
M. Rossi,
P. Brigidi,
R. Johansson,
A. Ferrieri,
G. Poggioli, and M. Campieri.
1999.
Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis.
Aliment. Pharmacol. Ther.
13:713-718[CrossRef][Medline].
|
| 18.
|
Hammer, R. E.,
S. D. Maika,
J. A. Richardson,
J. P. Tang, and J. D. Taurog.
1990.
Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders.
Cell
63:1099-1112[CrossRef][Medline].
|
| 19.
|
Hans, W.,
J. Scholmerich,
V. Gross, and W. Falk.
2000.
The role of the resident intestinal flora in acute and chronic dextran sulfate sodium-induced colitis in mice.
Eur. J. Gastroenterol. Hepatol.
12:267-273[Medline].
|
| 20.
|
Kojouharoff, G.,
W. Hans,
F. Obermeier,
D. N. Mannel,
T. Andus,
J. Scholmerich,
V. Gross, and W. Falk.
1997.
Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice.
Clin. Exp. Immunol.
107:353-358[CrossRef][Medline].
|
| 21.
|
Krook, A.,
G. Jarnerot, and D. Danielsson.
1981.
Clinical effect of metronidazole and sulfasalazine on Crohn's disease in relation to changes in the fecal flora.
Scand. J. Gastroenterol.
16:569-575[Medline].
|
| 22.
|
Kühn, R.,
J. Löhler,
D. Rennick,
K. Rajewsky, and W. Müller.
1993.
Interleukin-10-deficient mice develop chronic enterocolitis.
Cell
75:263-274[CrossRef][Medline].
|
| 23.
|
Lichtman, S. N.,
J. Keku,
J. H. Schwab, and R. B. Sartor.
1991.
Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline.
Gastroenterology
100:513-519[Medline].
|
| 24.
|
Lichtman, S. N.,
R. B. Sartor,
J. Keku, and J. H. Schwab.
1990.
Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth.
Gastroenterology
98:414-423[Medline].
|
| 25.
|
Lichtman, S. N.,
J. Wang,
R. B. Sartor,
C. Zhang,
D. Bender,
F. G. Dalldorf, and J. H. Schwab.
1995.
Reactivation of arthritis induced by small bowel bacterial overgrowth in rats: role of cytokines, bacteria, and bacterial polymers.
Infect. Immun.
63:2295-2301[Abstract].
|
| 26.
|
Madsen, K. L.,
J. S. Doyle,
M. M. Tavernini,
L. D. Jewell,
R. P. Rennie, and R. N. Fedorak.
2000.
Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice.
Gastroenterology
118:1094-1105[CrossRef][Medline].
|
| 27.
|
Mourelle, M.,
A. Salas,
F. Guarner,
E. Crespo,
A. Garcia-Lafuente, and J. R. Malagelada.
1998.
Stimulation of transforming growth factor beta1 by enteric bacteria in the pathogenesis of rat intestinal fibrosis.
Gastroenterology
114:519-526[CrossRef][Medline].
|
| 28.
|
Ohkusa, T.,
I. Okayasu,
S. Tokoi,
A. Araki, and Y. Ozaki.
1995.
Changes in bacterial phagocytosis of macrophages in experimental ulcerative colitis.
Digestion
56:159-164[CrossRef][Medline].
|
| 29.
|
Ohkusa, T.,
M. Yamada,
T. Takenaga,
C. Kitazume,
N. Yamamoto,
M. Sasabe,
I. Takashimizu,
Y. Tamura,
E. Sakamoto,
H. Kurosawa, et al.
1987.
Protective effect of metronidazole in experimental ulcerative colitis induced by dextran sulfate sodium.
Nippon. Shokakibyo. Gakkai. Zasshi.
84:2337-2346[Medline].
|
| 30.
|
Okayasu, I.,
S. Hatakeyama,
M. Yamada,
T. Ohkusa,
Y. Inagaki, and R. Nakaya.
1990.
A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice.
Gastroenterology
98:694-702[Medline].
|
| 31.
|
Onderdonk, A. B.,
M. L. Franklin, and R. L. Cisneros.
1981.
Production of experimental ulcerative colitis in gnotobiotic guinea pigs with simplified microflora.
Infect. Immun.
32:225-231[Abstract/Free Full Text].
|
| 32.
|
Onderdonk, A. B.,
J. A. Hermos,
J. L. Dzink, and J. G. Bartlett.
1978.
Protective effect of metronidazole in experimental ulcerative colitis.
Gastroenterology
74:521-526[Medline].
|
| 33.
|
Onderdonk, A. B.,
J. A. Richardson,
R. E. Hammer, and J. D. Taurog.
1998.
Correlation of cecal microflora of HLA-B27 transgenic rats with inflammatory bowel disease.
Infect. Immun.
66:6022-6023[Abstract/Free Full Text].
|
| 34.
|
Pankuch, G. A.,
M. R. Jacobs, and P. C. Appelbaum.
1993.
Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
Antimicrob. Agents Chemother.
37:1649-1654[Abstract/Free Full Text].
|
| 35.
|
Prantera, C.,
F. Zannoni,
M. L. Scribano,
E. Berto,
A. Andreoli,
A. Kohn, and C. Luzi.
1996.
An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin.
Am. J. Gastroenterol.
91:328-332[Medline].
|
| 36.
|
Rath, H. C.,
H. H. Herfarth,
J. S. Ikeda,
W. B. Grenther,
T. E. Hamm, Jr.,
E. Balish,
J. D. Taurog,
R. E. Hammer,
K. H. Wilson, and R. B. Sartor.
1996.
Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats.
J. Clin. Invest.
98:945-953[Medline].
|
| 37.
|
Rath, H. C.,
J. S. Ikeda,
H. J. Linde,
J. Scholmerich,
K. H. Wilson, and R. B. Sartor.
1999.
Varying cecal bacterial loads influences colitis and gastritis in HLA-B27 transgenic rats.
Gastroenterology
116:310-319[CrossRef][Medline].
|
| 38.
|
Rath, H. C.,
K. H. Wilson, and R. B. Sartor.
1999.
Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli.
Infect. Immun.
67:2969-2974[Abstract/Free Full Text].
|
| 39.
|
Rutgeerts, P.,
M. Hiele,
K. Geboes,
M. Peeters,
F. Penninckx,
R. Aerts, and R. Kerremans.
1995.
Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection.
Gastroenterology
108:1617-1621[CrossRef][Medline].
|
| 40.
|
Sartor, R. B.
1995.
Insights into the pathogenesis of inflammatory bowel disease provided by new rodent models of spontaneous colitis.
Inflamm. Bowel Dis.
1:64-75.
|
| 41.
|
Sartor, R. B.
1999.
Microbial factors in the pathogenesis of Crohn's disease, ulcerative colitis and experimental intestinal inflammation, p. 153-178.
In
J. B. Kirsner (ed.), Inflammatory bowel disease. Williams & Wilkins, Baltimore, Md.
|
| 42.
|
Sartor, R. B.
2000.
Colitis in HLA-B27/beta 2 microglobulin transgenic rats.
Int. Rev. Immunol.
19:39-50[Medline].
|
| 43.
|
Sartor, R. B.,
H. C. Rath, and R. K. Sellon.
1996.
Microbial factors in chronic intestinal inflammation.
Curr. Opin. Gastroenterol.
12:327-333.
|
| 44.
|
Schultz, M.,
S. L. Tonkonogy,
R. K. Sellon,
C. Veltkamp,
V. L. Godfrey,
J. Kwon,
W. B. Grenther,
E. Balish,
I. Horak, and R. B. Sartor.
1999.
IL-2-deficient mice raised under germfree conditions develop delayed mild focal intestinal inflammation.
Am. J. Physiol.
276:G1461-G1472[Abstract/Free Full Text].
|
| 45.
|
Sellon, R. K.,
S. L. Tonkonogy, and M. Schultz.
1998.
Normal enteric flora are necessary for the development of spontaneous colitis and immune system activation in IL-10 deficient mice.
Infect. Immun.
66:5224-5231[Abstract/Free Full Text].
|
| 46.
|
Summanen, P. (ed.).
1993.
Wadsworth anaerobic bacteriology manual.
Star Publishing Co., Belmont, Calif.
|
| 47.
|
Sutherland, L.,
J. Singleton,
J. Sessions,
S. Hanauer,
E. Krawitt,
G. Rankin,
R. Summers,
H. Mekhjian,
N. Greenberger,
M. Kelly,
J. Levine,
A. Thomson,
E. Alpert, and E. Prokipchuk.
1991.
Double blind, placebo controlled trial of metronidazole in Crohn's disease.
Gut
32:1071-1075[Abstract/Free Full Text].
|
| 48.
|
Taurog, J. D.,
S. D. Maika,
W. A. Simmons,
M. Breban, and R. E. Hammer.
1993.
Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression.
J. Immunol.
150:4168-4178[Abstract].
|
| 49.
|
Taurog, J. D.,
J. A. Richardson,
J. T. Croft,
W. A. Simmons,
M. Zhou,
J. L. Fernandez Sueiro,
E. Balish, and R. E. Hammer.
1994.
The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats.
J. Exp. Med.
180:2359-2364[Abstract/Free Full Text].
|
| 50.
|
Tlaskalova, H.,
R. Stephankova,
T. Hudcovic,
B. Cukrowska,
E. Verdu,
L. Tuckova,
L. Jelinkova,
F. Bend-Jelloul,
Z. Rehakova,
J. Sinkora,
D. Sokol,
P. Bercik,
D. Funda,
P. Michetti, and J. Cebra.
1999.
The role of bacterial microflora in the development of dextran sodium sulphate (DSS) induced colitis in immunocompetent and immunodeficient mice.
Microb. Ecol. Health Dis.
11:115-116.
|
| 51.
|
Turunen, U. M.,
M. A. Farkkila,
K. Hakala,
K. Seppaia,
A. Sivonen,
M. Ogren,
M. Vuoristo,
V. V. Valtonen, and T. A. Miettinen.
1998.
Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study.
Gastroenterology
115:1072-1078[CrossRef][Medline].
|
| 52.
|
Veltkamp, C.,
S. L. Tonkonogy,
Y. P. de Yong,
W. B. Grenther,
E. Balish,
C. Terhorst, and R. B. Sartor.
2001.
Continuous stimulation by normal luminal bacteria is essential for the development and perpetuation of colitis in Tg 26 mice after bone marrow transplantation or adoptive transfer.
Gastroenterology
120:900-913[CrossRef][Medline].
|
| 53.
|
Videla, S.,
J. Vilaseca,
F. Guarner,
A. Salas,
F. Treserra,
E. Crespo,
M. Antolin, and J. R. Malagelada.
1994.
Role of intestinal microflora in chronic inflammation and ulceration of the rat colon.
Gut
35:1090-1097[Abstract/Free Full Text].
|
| 54.
|
Yamada, T.,
E. Deitch,
R. D. Specian,
M. A. Perry,
R. B. Sartor, and M. B. Grisham.
1993.
Mechanisms of acute and chronic intestinal inflammation induced by indomethacin.
Inflammation
17:641-662[CrossRef][Medline].
|
Infection and Immunity, April 2001, p. 2277-2285, Vol. 69, No. 4
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.4.2277-2285.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Gareau, M. G, Jury, J., MacQueen, G., Sherman, P. M, Perdue, M. H
(2007). Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation. Gut
56: 1522-1528
[Abstract]
[Full Text]
-
Dotan, I., Allez, M., Nakazawa, A., Brimnes, J., Schulder-Katz, M., Mayer, L.
(2007). Intestinal epithelial cells from inflammatory bowel disease patients preferentially stimulate CD4+ T cells to proliferate and secrete interferon-{gamma}. Am. J. Physiol. Gastrointest. Liver Physiol.
292: G1630-G1640
[Abstract]
[Full Text]
-
Heimesaat, M. M., Bereswill, S., Fischer, A., Fuchs, D., Struck, D., Niebergall, J., Jahn, H.-K., Dunay, I. R., Moter, A., Gescher, D. M., Schumann, R. R., Gobel, U. B., Liesenfeld, O.
(2006). Gram-Negative Bacteria Aggravate Murine Small Intestinal Th1-Type Immunopathology following Oral Infection with Toxoplasma gondii. J. Immunol.
177: 8785-8795
[Abstract]
[Full Text]
-
Medina, C., Radomski, M. W.
(2006). Role of Matrix Metalloproteinases in Intestinal Inflammation. J. Pharmacol. Exp. Ther.
318: 933-938
[Abstract]
[Full Text]
-
Strauch, U G, Obermeier, F, Grunwald, N, Gurster, S, Dunger, N, Schultz, M, Griese, D P, Mahler, M, Scholmerich, J, Rath, H C
(2005). Influence of intestinal bacteria on induction of regulatory T cells: lessons from a transfer model of colitis. Gut
54: 1546-1552
[Abstract]
[Full Text]
-
Stremmel, W, Merle, U, Zahn, A, Autschbach, F, Hinz, U, Ehehalt, R
(2005). Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut
54: 966-971
[Abstract]
[Full Text]
-
Fukata, M., Michelsen, K. S., Eri, R., Thomas, L. S., Hu, B., Lukasek, K., Nast, C. C., Lechago, J., Xu, R., Naiki, Y., Soliman, A., Arditi, M., Abreu, M. T.
(2005). Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am. J. Physiol. Gastrointest. Liver Physiol.
288: G1055-G1065
[Abstract]
[Full Text]
-
Kieper, W. C., Troy, A., Burghardt, J. T., Ramsey, C., Lee, J. Y., Jiang, H.-Q., Dummer, W., Shen, H., Cebra, J. J., Surh, C. D.
(2005). Cutting Edge: Recent Immune Status Determines the Source of Antigens That Drive Homeostatic T Cell Expansion. J. Immunol.
174: 3158-3163
[Abstract]
[Full Text]
-
Maeda, S., Hsu, L.-C., Liu, H., Bankston, L. A., Iimura, M., Kagnoff, M. F., Eckmann, L., Karin, M.
(2005). Nod2 Mutation in Crohn's Disease Potentiates NF-{kappa}B Activity and IL-1{beta} Processing. Science
307: 734-738
[Abstract]
[Full Text]
-
Rachinel, N., Buzoni-Gatel, D., Dutta, C., Mennechet, F. J. D., Luangsay, S., Minns, L. A., Grigg, M. E., Tomavo, S., Boothroyd, J. C., Kasper, L. H.
(2004). The Induction of Acute Ileitis by a Single Microbial Antigen of Toxoplasma gondii. J. Immunol.
173: 2725-2735
[Abstract]
[Full Text]
-
Schultz, M., Munro, K., Tannock, G. W., Melchner, I., Gottl, C., Schwietz, H., Scholmerich, J., Rath, H. C.
(2004). Effects of Feeding a Probiotic Preparation (SIM) Containing Inulin on the Severity of Colitis and on the Composition of the Intestinal Microflora in HLA-B27 Transgenic Rats. CVI
11: 581-587
[Abstract]
[Full Text]
-
Schultz, M., Strauch, U. G., Linde, H.-J., Watzl, S., Obermeier, F., Gottl, C., Dunger, N., Grunwald, N., Scholmerich, J., Rath, H. C.
(2004). Preventive Effects of Escherichia coli Strain Nissle 1917 on Acute and Chronic Intestinal Inflammation in Two Different Murine Models of Colitis. CVI
11: 372-378
[Abstract]
[Full Text]
-
Furrie, E, Macfarlane, S, Cummings, J H, Macfarlane, G T
(2004). Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response. Gut
53: 91-98
[Abstract]
[Full Text]
-
Alyanakian, M.-A., You, S., Damotte, D., Gouarin, C., Esling, A., Garcia, C., Havouis, S., Chatenoud, L., Bach, J.-F.
(2003). Diversity of regulatory CD4+T cells controlling distinct organ-specific autoimmune diseases. Proc. Natl. Acad. Sci. USA
100: 15806-15811
[Abstract]
[Full Text]
-
Hoentjen, F, Harmsen, H J M, Braat, H, Torrice, C D, Mann, B A, Sartor, R B, Dieleman, L A
(2003). Antibiotics with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in interleukin 10 gene deficient mice. Gut
52: 1721-1727
[Abstract]
[Full Text]
-
Pavan, S., Desreumaux, P., Mercenier, A.
(2003). Use of Mouse Models To Evaluate the Persistence, Safety, and Immune Modulation Capacities of Lactic Acid Bacteria. CVI
10: 696-701
[Abstract]
[Full Text]
-
Ortega-Cava, C. F., Ishihara, S., Rumi, M. A. K., Kawashima, K., Ishimura, N., Kazumori, H., Udagawa, J., Kadowaki, Y., Kinoshita, Y.
(2003). Strategic Compartmentalization of Toll-Like Receptor 4 in the Mouse Gut. J. Immunol.
170: 3977-3985
[Abstract]
[Full Text]
-
Dieleman, L A, Goerres, M S, Arends, A, Sprengers, D, Torrice, C, Hoentjen, F, Grenther, W B, Sartor, R B
(2003). Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut
52: 370-376
[Abstract]
[Full Text]
-
Melmed, G., Thomas, L. S., Lee, N., Tesfay, S. Y., Lukasek, K., Michelsen, K. S., Zhou, Y., Hu, B., Arditi, M., Abreu, M. T.
(2003). Human Intestinal Epithelial Cells Are Broadly Unresponsive to Toll-Like Receptor 2-Dependent Bacterial Ligands: Implications for Host-Microbial Interactions in the Gut. J. Immunol.
170: 1406-1415
[Abstract]
[Full Text]
-
Wei, B., Huang, T., Dalwadi, H., Sutton, C. L., Bruckner, D., Braun, J.
(2002). Pseudomonas fluorescens Encodes the Crohn's Disease-Associated I2 Sequence and T-Cell Superantigen. Infect. Immun.
70: 6567-6575
[Abstract]
[Full Text]
-
Bamias, G., Marini, M., Moskaluk, C. A., Odashima, M., Ross, W. G., Rivera-Nieves, J., Cominelli, F.
(2002). Down-Regulation of Intestinal Lymphocyte Activation and Th1 Cytokine Production by Antibiotic Therapy in a Murine Model of Crohn's Disease. J. Immunol.
169: 5308-5314
[Abstract]
[Full Text]
-
Podolsky, D. K.
(2002). Inflammatory Bowel Disease. NEJM
347: 417-429
[Full Text]
-
Iqbal, N., Oliver, J. R., Wagner, F. H., Lazenby, A. S., Elson, C. O., Weaver, C. T.
(2002). T Helper 1 and T Helper 2 Cells Are Pathogenic in an Antigen-specific Model of Colitis. J. Exp. Med.
195: 71-84
[Abstract]
[Full Text]